European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Slides:

Advertisements

Similar presentations

Medical Management for BPH: The Role of Combination Therapy

Advertisements

Volume 172, Issue 6, Pages (December 2004)

Pascal Rischmann European Urology Supplements

Fred Saad European Urology Supplements

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

European Urology Oncology

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Bladder Cancer: Management and Future Directions

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 66, Issue 3, Pages (September 2014)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 66, Issue 2, Pages (August 2014)

Volume 52, Issue 5, Pages (November 2007)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Management: What Does the Future Hold?

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Luis Martínez-Piñeiro European Urology Supplements

Richard C. Harkaway European Urology Supplements

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Surgical Management of Renal Cell Carcinoma (RCC) with Vena Cava Tumour Thrombus Emanuele Belgrano, Carlo Trombetta, Salvatore Siracusano, Giorgio Carmignani,

Jacques Irani European Urology Supplements

Kidney Cancer: Highlights from 2006

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Bernard Escudier European Urology Supplements

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The Hallmarks of BPH Progression and Risk Factors

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

Volume 68, Issue 5, Pages (November 2015)

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Axel Heidenreich European Urology Supplements

Profile of Silodosin European Urology Supplements

Highlighting Unmet Needs: Real Patients, Difficult Choices

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Volume 375, Issue 9715, Pages (February 2010)

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

European Urology Oncology

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Michael Marberger European Urology Supplements

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Presentation transcript:

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard European Urology Supplements Volume 7, Issue 2, Pages 46-54 (February 2008) DOI: 10.1016/j.eursup.2007.12.002 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Progression-free survival by investigator assessment in the phase 2 studies of sunitinib as second-line therapy (pooled population, n=168) [15]. Copyright © 2006, American Medical Association. All rights reserved. European Urology Supplements 2008 7, 46-54DOI: (10.1016/j.eursup.2007.12.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Effect of baseline factors on progression-free survival in the phase 3 trial of sunitinib versus interferon-α [16]. Data were missing for time since diagnosis for 15 patients and for haemoglobin level and corrected serum calcium for 16 patients. ECOG=Eastern Cooperative Oncology Group; LLN=lower limit of the normal range; ULN=upper limit of the normal range. Copyright © 2007 Massachusetts Medical Society. All rights reserved. European Urology Supplements 2008 7, 46-54DOI: (10.1016/j.eursup.2007.12.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier estimates of (A) overall survival and (B) investigator-assessed progression-free survival among 903 patients in the phase 3 trial of second-line sorafenib versus interferon-α [24]. Panel A: p=0.02 for the comparison between the two study groups; threshold for statistical significance p=0.0005; panel B: p<0.001. Copyright © 2007 Massachusetts Medical Society. All rights reserved. European Urology Supplements 2008 7, 46-54DOI: (10.1016/j.eursup.2007.12.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival in the phase 3 study comparing temsirolimus with interferon-α (IFN-α) alone and temsirolimus in combination with IFN-α as first-line therapy in poor-risk patients [27]. Copyright © 2007 Massachusetts Medical Society. All rights reserved. European Urology Supplements 2008 7, 46-54DOI: (10.1016/j.eursup.2007.12.002) Copyright © 2007 European Association of Urology Terms and Conditions